J&J's TMC435 Joins The Pharmasset Club
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmasset and J&J's Tibotec unit will initiate a Phase II study evaluating the combination of the investigational nucleotide polymerase inhibitor PSI-7977 and protease inhibitor TMC435.